Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
about
Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusAssociations between medication use and homocysteine levels in an older population, and potential mediation by vitamin B12 and folate: data from the B-PROOF Study.Diabetes: glycaemic control in type 2.Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus.Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.Repaglinide: a review of its use in type 2 diabetes mellitus.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update.Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial.Inverse association between plasma homocysteine, sulphonylurea exposure and physical activity: a community-based sample of type 2 diabetes patients in the Skaraborg hypertension and diabetes project.Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
P2860
Q24186660-4A7EB615-D23E-4027-ADC2-5764EC070F74Q24197884-503A7748-8C28-43B8-90EF-8AAFC8BC09ABQ30835074-4E766BCD-BE80-4CEE-BC49-C77072F5A69CQ33446693-7E47299B-5153-4738-AF73-CBFA459EFD24Q36104044-4A85E10B-2B7E-4C2F-9BDC-E479E75187B7Q36359500-405F5D06-8D35-49D0-BCA0-2B6E661F6FB7Q36390892-6DAAD4B8-E09C-487C-A346-0051BD8FAE0EQ37321871-35269848-20BA-419F-9E69-9968DE1F91AEQ37541529-0ADD7800-81AE-4972-B2A0-C566435C9527Q37977979-CB1D3B53-0F1C-425D-B5D1-652B555D6D5EQ38524435-E859E236-E90C-4631-A0E7-143790C886C1Q40844288-2E4CC62A-5290-4441-A6E7-C01A4AE209A5Q42253351-DF9B7C1C-B65B-40D2-8837-36EF12EC889EQ43242160-D210B759-0515-4901-955F-401E56101D9FQ43409321-70232996-FCB1-458F-B787-4E06482F9F3FQ46495618-E0134250-E2D3-4C02-8C5C-97FD52370DB1Q46530085-0B402DAA-DDDF-4923-9644-B0BB86E647FCQ46545851-A651F761-3258-4B52-A689-E0D485C85713Q46920671-40112492-0455-450F-83AB-7A107A4493F9Q51370461-4B123FBA-0AEB-460B-B82A-F6C0C9E1317FQ51468978-52C75886-3656-4992-BED3-228942C7071F
P2860
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Comparison between repaglinide ...... d cardiovascular risk factors.
@en
Comparison between repaglinide ...... d cardiovascular risk factors.
@nl
type
label
Comparison between repaglinide ...... d cardiovascular risk factors.
@en
Comparison between repaglinide ...... d cardiovascular risk factors.
@nl
prefLabel
Comparison between repaglinide ...... d cardiovascular risk factors.
@en
Comparison between repaglinide ...... d cardiovascular risk factors.
@nl
P2093
P1476
Comparison between repaglinide ...... d cardiovascular risk factors.
@en
P2093
Amedeo Mugellini
Giuseppe Crescenzi
Leonardina Ciccarelli
Roberto Fogari
P304
P356
10.1016/S0149-2918(03)80090-5
P577
2003-02-01T00:00:00Z